Wave Life Sciences (WVE) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Wave Life Sciences (WVE) over the past year, gaining 5.3% versus a loss of 57.8%. Over five years, ZVRA leads with a +16.6% price change compared with -32.8% for WVE. Wave Life Sciences is the larger company by market cap ($681.8 million vs $676.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | WVE | ZVRA |
|---|---|---|
| Share price | $3.46 | $11.39 |
| Market cap | $681.79M | $676.38M |
| 1-day change | -0.29% | +3.55% |
| YTD return | -79.65% | +27.12% |
| 1-year return | -57.75% | +5.27% |
| 5-year return | -32.82% | +16.58% |
| P/E ratio (TTM) | — | 11.99 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-1.08 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.73 | $15.04 |
| 52-week low | $3.37 | $8.01 |
| Distance from 52-week high | -84.08% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +421.97% | +119.49% |
| Average volume | 3.09M | 1.09M |
| Shares outstanding | 197.05M | 59.38M |
| Employees | 317 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed WVE by 63.0 percentage points over the past year.
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
WVE vs ZVRA FAQ
Which is bigger, Wave Life Sciences or Zevra Therapeutics?
Wave Life Sciences (WVE) is larger, with a market capitalization of $681.79M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, WVE or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -57.75% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Wave Life Sciences and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.